With the availability of daratumumab and other anti‐CD38 antibodies, epigenetic priming to upregulate CD38 before antibody treatment has been studied in multiple myeloma and is also pursued in AML treatment by several groups, such as Buteyn et al. This evidence concerns the gene CD38 and plasma cell myeloma.